HPV vaccination South Africa: Cervical Cancer Prevention

By Crystal Lubbe

November 21, 2024

Since the launch of South Africa’s HPV vaccination program, the country has made notable progress in addressing cervical cancer. The HPV vaccination program, introduced in 2014, specifically targets 9-year-old girls in grade four across over 12,000 public schools. Despite challenges posed by the COVID-19 pandemic, the program has achieved impressive vaccination coverage rates. Furthermore, averaging between 70% to 80% prior to the pandemic’s disruption.

Program Implementation and Coverage

The national HPV vaccination program is integrated into the Integrated School Health Program. Therefore, utilising school nurses and a dedicated workforce of vaccinators. This effective delivery method is crucial for reaching the intended target population.

Vaccine Efficacy and Single-Dose Regimen

Global studies reveal that HPV vaccines can decrease cervical cancer rates by up to 90% in girls who receive the vaccination. The recent consideration of a single-dose regimen is promising, as it could streamline the vaccination process and lower the costs associated with the immunization campaign.

Impact on Cervical Cancer

Approximately 70% of cervical cancer cases worldwide are linked to HPV types 16 and 18. By preventing these infections through the HPV vaccination program, South Africa aims to significantly reduce not only the incidence of cervical cancer but also other anogenital cancers.

Challenges and Additional Strategies

Women living with HIV (WLHIV) face a heightened risk of developing cervical cancer. To combat this issue, additional strategies, including more frequent cervical screenings for WLHIV, are being explored to work towards the elimination of cervical cancer among this demographic.

Public Health and Policy Implications

The successful implementation of South Africa’s HPV vaccination program positions it as a model for other nations, aligning with the World Health Organization’s initiative to eradicate cervical cancer as a public health problem. Furthermore, the program’s infrastructure supports broader adolescent health efforts.

Funding and Advocacy

The ongoing success of the HPV vaccination program relies on dedicated funding and robust advocacy. Framing the vaccination as a vital cancer prevention tool, rather than merely a defense against a sexually transmitted infection, has bolstered public support for the initiative.

In summary, South Africa’s HPV vaccination program exemplifies significant progress in combating cervical cancer. With strong coverage rates, integration into school health services, the exploration of a single-dose regimen, and targeted strategies for at-risk groups, the nation is setting a positive example for others to follow.

Reference url

Recent Posts

Health Investment Returns: Harnessing Health as a Strategic Economic Asset

By João L. Carapinha

November 18, 2025

Health as a Strategic Economic Imperative A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recent EFPIA Guest Blog by Michael Oberreiter frames he...
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gram-Negative Infections
Emblaveo Approved for MDR Gram-Negative Infections Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avibactam) for financing under Decree-Law No. 97/2015....
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line Therapy

By HEOR Staff Writer

November 17, 2025

Sacituzumab Govitecan Shows Promise in First-Line TNBC Therapy Sacituzumab govitecan for TNBC represents a major step forward in treating untreated